Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06653842 · ClinicalTrials.gov registry record · Phase 2
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
A Phase 2 study of Cutaneous Venous Malformations, sponsored by Palvella Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 10
- Study locations
NCT06653842: Recruiting Phase 2 study of Cutaneous Venous Malformations, sponsored by Palvella Therapeutics.
NCT06653842 is a Phase 2 study of Cutaneous Venous Malformations that is actively recruiting participants, run by Palvella Therapeutics. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06653842, a Phase 2 study of Cutaneous Venous Malformations, is actively recruiting participants, sponsored by Palvella Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 10
- Study locations
Study Summary
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Conditions Studied
Interventions
- DRUG QTORIN 3.9% rapamycin anhydrous gel
Study Locations (10)
California
- Children's Hospital of Orange County - Irvine
- Stanford University - Palo Alto
Minnesota
- Minnesota Clinical Study Center - New Brighton
- Mayo Clinic - Rochester
Colorado
- Colorado Children's Hospital - Aurora
Maryland
- Johns Hopkins - Baltimore
North Carolina
- University of North Carolina - Chapel Hill
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Utah
- University of Utah Health - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2024-12-20 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What NCT06653842 shows while recruiting
NCT06653842 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Cutaneous Venous Malformations appearing as the primary indexed condition, and to 1 intervention - of which QTORIN 3.9% rapamycin anhydrous gel is the first listed.
NCT06653842 lists 10 locations in 8 states (California, Minnesota, Colorado).
Frequently Asked Questions
What is clinical trial NCT06653842 about?
NCT06653842 is a clinical study titled "A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations". A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
What is the current status of trial NCT06653842?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2024-12-20. Estimated completion is 2026-03.
What conditions does trial NCT06653842 study?
This clinical trial studies the following conditions: Cutaneous Venous Malformations.
What interventions are being tested in trial NCT06653842?
The interventions under investigation include: QTORIN 3.9% rapamycin anhydrous gel (DRUG).
Who is sponsoring clinical trial NCT06653842?
This trial is sponsored by Palvella Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06653842 being conducted?
This trial has 10 study locations across California, Colorado, Maryland, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06653842's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI